Featured news from NHIVNA
HIV-related news from NAM
Package of prophylaxis against infections reduces the risk of death for people starting HIV treatment very late
Keith Alcorn, 2016-08-08 07:10:00
A package of enhanced prophylaxis against infections
significantly reduced the risk of death in adults and children with advanced
HIV disease after starting antiretroviral treatment in a randomised study,
Professor James Hakim of the University of Zimbabwe told the 21st
International AIDS Conference in Durban, South Africa, last month.
Professor Hakim was presenting the results of the REALITY
study, a large clinical trial designed to evaluate strategies for reducing the
risk of death in people who start antiretroviral treatment with very low CD4
cell counts (below 100 cells/mm3). Late presentation with HIV disease, often
with symptomatic disease, remains common in sub-Saharan Africa. The risk of
death in the first six months after starting treatment remains high for adults
Professor Hakim told a press conference that death rates in
the first six months of treatment can be six to ten times higher in low and
middle-income countries than in the developed world in people who start
treatment with very advanced HIV disease, due to infections such as
tuberculosis (TB) and Cryptococcus, and due to severe malnourishment.
Identifying ways of reducing the risk of death in people who
start antiretroviral therapy with very low CD4 counts is essential if the
number of AIDS-related deaths is to be reduced. In particular, more evidence is needed to show whether a package of aggressive prophylaxis against the infections that most frequently cause deaths in the first months after starting ART can bring down death rates. Although cotrimoxazole prophylaxis is widely implemented, isoniazid preventive treatment still fails to be provided despite a World Health Organization recommendation for its use in people living with HIV.
The REALITY trial, carried out in Kenya, Malawi, Uganda and
Zimbabwe evaluated three strategies for reducing the risk of death:
- Prophylaxis against the infections most commonly
associated with death in advanced HIV disease (tuberculosis, cryptoccus,
bacterial infections and protozoal infections), compared to cotrimoxazole
- Intensification of antiretroviral therapy with
an integrase inhibitor in order to reduce viral load more quickly, leading to
more rapid immune reconstitution, compared to three-drug ART alone.
- Supplementary ready-to-use food for 12 weeks
(two packets of a high energy, low protein food per day) to improve nutrition,
compared to targeted nutritional support for those with poor nutritional status
according to local protocols.
All participants in the study received antiretroviral therapy
according to national guidelines (predominantly tenofovir/emtricitabine and
efavirenz). In addition, participants underwent three randomisations (factorial
randomisation), to each of the study interventions or to a control arm.
Participants were therefore randomised to one intervention and then each group
was randomised to receive a further intervention or control, and so on.